Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
- 15 June 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (12), 3117-3125
- https://doi.org/10.1200/jco.2001.19.12.3117
Abstract
PURPOSE: To develop a combination of pegylated liposomal doxorubicin (Doxil; Alza Pharmaceuticals, Palo Alto, CA) and docetaxel (Taxotere; Aventis Pharmaceutical, Parsipanny, NJ) that can be safely...Keywords
This publication has 30 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Taxanes for Breast Cancer: An Evidence-Based Review of Randomized Phase II and Phase III TrialsClinical Breast Cancer, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- 650: Taxotere™ (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)European Journal Of Cancer, 1997
- Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacyJournal of Neurosurgery, 1995
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- Cytoskeletal agents inhibit motility and adherence of human tumor cellsKidney International, 1993
- Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomesInternational Journal of Cancer, 1992
- Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscopeJournal of Molecular Biology, 1964
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958